Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

What role do periodontal pathogens play in osteoarthritis and periprosthetic joint infections of the knee?

Ehrlich GD, Hu FZ, Sotereanos N, Sewicke J, Parvizi J, Nara PL, Arciola CR.

J Appl Biomater Funct Mater. 2014 Jun 12;12(1):13-20. doi: 10.5301/jabfm.5000203.

PMID:
24921460
2.

Antibody neutralization of retargeted measles viruses.

Lech PJ, Pappoe R, Nakamura T, Tobin GJ, Nara PL, Russell SJ.

Virology. 2014 Apr;454-455:237-46. doi: 10.1016/j.virol.2014.01.027. Epub 2014 Mar 14. Erratum in: Virology. 2014 Sep;464-465:460. Tobin, Gregory J [added]; Nara, Peter L [added].

3.

Epitope dampening monotypic measles virus hemagglutinin glycoprotein results in resistance to cocktail of monoclonal antibodies.

Lech PJ, Tobin GJ, Bushnell R, Gutschenritter E, Pham LD, Nace R, Verhoeyen E, Cosset FL, Muller CP, Russell SJ, Nara PL.

PLoS One. 2013;8(1):e52306. doi: 10.1371/journal.pone.0052306. Epub 2013 Jan 3.

4.

Antibody repertoire development in fetal and neonatal piglets XXI. Usage of most VH genes remains constant during fetal and postnatal development.

Butler JE, Sun X, Wertz N, Lager KM, Chaloner K, Urban J Jr, Francis DL, Nara PL, Tobin GJ.

Mol Immunol. 2011 Dec;49(3):483-94. doi: 10.1016/j.molimm.2011.09.018. Epub 2011 Oct 21.

PMID:
22018637
5.

Evolution of H3N2 influenza virus in a guinea pig model.

Long J, Bushnell RV, Tobin JK, Pan K, Deem MW, Nara PL, Tobin GJ.

PLoS One. 2011;6(7):e20130. doi: 10.1371/journal.pone.0020130. Epub 2011 Jul 22.

6.

How can vaccines against influenza and other viral diseases be made more effective?

Nara PL, Tobin GJ, Chaudhuri AR, Trujillo JD, Lin G, Cho MW, Levin SA, Ndifon W, Wingreen NS.

PLoS Biol. 2010 Dec 21;8(12):e1000571. doi: 10.1371/journal.pbio.1000571. No abstract available.

7.

Selective pressure to increase charge in immunodominant epitopes of the H3 hemagglutinin influenza protein.

Pan K, Long J, Sun H, Tobin GJ, Nara PL, Deem MW.

J Mol Evol. 2011 Jan;72(1):90-103. doi: 10.1007/s00239-010-9405-4. Epub 2010 Nov 18.

8.
9.

Brucellosis as a Transboudary Infection of Animals and Humans which Needs to be Managed by Cooperative Efforts of Different Countries. Introduction.

Wolfram JH, Nara PL.

Vaccine. 2010 Oct 1;28 Suppl 5:F1-2. doi: 10.1016/j.vaccine.2010.04.022. No abstract available.

PMID:
20850687
10.

Serological characterization of guinea pigs infected with H3N2 human influenza or immunized with hemagglutinin protein.

Bushnell RV, Tobin JK, Long J, Schultz-Cherry S, Chaudhuri AR, Nara PL, Tobin GJ.

Virol J. 2010 Aug 24;7:200. doi: 10.1186/1743-422X-7-200.

11.

Deceptive imprinting and immune refocusing in vaccine design.

Tobin GJ, Trujillo JD, Bushnell RV, Lin G, Chaudhuri AR, Long J, Barrera J, Pena L, Grubman MJ, Nara PL.

Vaccine. 2008 Nov 18;26(49):6189-99. doi: 10.1016/j.vaccine.2008.09.080. Epub 2008 Oct 11.

PMID:
18852005
12.

Perspectives on advancing preventative medicine through vaccinology at the comparative veterinary, human and conservation medicine interface: not missing the opportunities.

Nara PL, Nara D, Chaudhuri R, Lin G, Tobin G.

Vaccine. 2008 Nov 18;26(49):6200-11. doi: 10.1016/j.vaccine.2008.07.094. Epub 2008 Aug 15.

PMID:
18708109
13.
14.

Advances in immunology and vaccine discovery report of the United States-European Commission workshop.

Gay CG, Richie TL, Pastoret PP, Minguez-Tudela I, de Baetselier P, Göbel T, Goddeeris B, Kaiser P, Morrison I, Sánchez-Vizcaíno JM, Anderson K, Baillie LW, Brown WC, Estes DM, Herrera E, Nara PL, Ockenhouse CF, Roth JA, Sztein MB.

Vaccine. 2007 Oct 10;25(41):7007-11. Epub 2007 Aug 6.

PMID:
17728022
15.

HIV-1: the confounding variables of virus neutralization.

Nara PL, Lin G.

Curr Drug Targets Infect Disord. 2005 Jun;5(2):157-70. Review.

PMID:
15975021
16.
17.

Few clues for AIDS vaccines from structural data on gp120 and its receptors and antibodies.

Kohler H, Muller S, Schiffer M, Nara PL.

J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Mar 1;20(3):315-6. No abstract available.

PMID:
10077183
18.
19.

Deceptive imprinting: insights into mechanisms of immune evasion and vaccine development.

Nara PL.

Adv Vet Med. 1999;41:115-34. Review. No abstract available.

PMID:
9890013
20.

Deceptive imprinting: a cosmopolitan strategy for complicating vaccination.

Nara PL, Garrity R.

Vaccine. 1998 Nov;16(19):1780-7. Review. No abstract available.

PMID:
9795381
21.

'An ounce of prevention'.

Nara PL.

Vaccine. 1998 Nov;16(19):1779. No abstract available.

PMID:
9795380
22.
23.

Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles.

Shankarappa R, Gupta P, Learn GH Jr, Rodrigo AG, Rinaldo CR Jr, Gorry MC, Mullins JI, Nara PL, Ehrlich GD.

Virology. 1998 Feb 15;241(2):251-9.

24.

Stimulation of HIV-1-neutralizing antibodies in simian HIV-IIIB-infected macaques.

Müller S, Margolin DH, Nara PL, Alvord WG, Köhler H.

Proc Natl Acad Sci U S A. 1998 Jan 6;95(1):276-81.

25.

Glycosylation affects both the three-dimensional structure and antibody binding properties of the HIV-1IIIB GP120 peptide RP135.

Huang X, Barchi JJ Jr, Lung FD, Roller PP, Nara PL, Muschik J, Garrity RR.

Biochemistry. 1997 Sep 9;36(36):10846-56.

PMID:
9312273
26.

Preliminary findings of an in vitro human spleen mononuclear cell culture system for primary isolates of HIV type 1.

Tsai WP, Rimelzwaan GF, Merges MJ, Wu SC, Conley S, Kung HF, Garrity R, Goudsmit J, Nara PL.

AIDS Res Hum Retroviruses. 1997 Jul 20;13(11):967-77.

PMID:
9223413
27.

Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.

Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, Gulakowski RJ, Wu L, Rivera MI, Laurencot CM, Currens MJ, Cardellina JH 2nd, Buckheit RW Jr, Nara PL, Pannell LK, Sowder RC 2nd, Henderson LE.

Antimicrob Agents Chemother. 1997 Jul;41(7):1521-30.

28.

Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope.

Garrity RR, Rimmelzwaan G, Minassian A, Tsai WP, Lin G, de Jong JJ, Goudsmit J, Nara PL.

J Immunol. 1997 Jul 1;159(1):279-89.

PMID:
9200464
31.

A cytopathic infectivity assay of human immunodeficiency virus type 1 in human primary macrophages.

Wu SC, Spouge JL, Merges MJ, Conley SR, Nara PL.

J Virol Methods. 1996 May;59(1-2):45-55.

PMID:
8793829
32.
33.

Immunotyping HIV-1 in the 1990s. WHO Collaborating Network.

Nara PL.

Antibiot Chemother (1971). 1996;48:56-62. Review. No abstract available.

PMID:
8726506
34.

Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.

Vancott TC, Polonis VR, Loomis LD, Michael NL, Nara PL, Birx DL.

AIDS Res Hum Retroviruses. 1995 Nov;11(11):1379-91.

PMID:
8573396
35.

Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.

Girard M, Meignier B, Barré-Sinoussi F, Kieny MP, Matthews T, Muchmore E, Nara PL, Wei Q, Rimsky L, Weinhold K, et al.

J Virol. 1995 Oct;69(10):6239-48.

37.

Analysis of B cell repertoire specific to the neutralizing epitopes of glycoprotein 120 in HIV-infected individuals.

Hariharan K, Nara PL, Shabazz LA, McCutchan JA, Kang CY.

AIDS Res Hum Retroviruses. 1994 Dec;10(12):1629-37.

PMID:
7888222
38.

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, et al.

Science. 1994 Nov 11;266(5187):1024-7.

PMID:
7973652
39.

Deceptive imprinting in the immune response against HIV-1.

Köhler H, Müller S, Nara PL.

Immunol Today. 1994 Oct;15(10):475-8. Review.

PMID:
7945772
41.

Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.

Pincus SH, Messer KG, Nara PL, Blattner WA, Colclough G, Reitz M.

J Clin Invest. 1994 Jun;93(6):2505-13.

42.

In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity.

Barbas CF 3rd, Hu D, Dunlop N, Sawyer L, Cababa D, Hendry RM, Nara PL, Burton DR.

Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3809-13.

43.

Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.

Back NK, Smit L, Schutten M, Nara PL, Tersmette M, Goudsmit J.

J Virol. 1993 Nov;67(11):6897-902.

45.

Analysis of the cross-reactive anti-gp120 antibody population in human immunodeficiency virus-infected asymptomatic individuals.

Hariharan K, Nara PL, Caralli VM, Norton FL, Haigwood N, Kang CY.

J Virol. 1993 Feb;67(2):953-60.

46.

Genotypic and phenotypic variation of HIV-1: impact on AIDS pathogenesis and vaccination.

Wolfs TF, Nara PL, Goudsmit J.

Chem Immunol. 1993;56:1-33. Review. No abstract available.

PMID:
8383980
47.

Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120.

Hansen BD, Nara PL, Maheshwari RK, Sidhu GS, Bernbaum JG, Hoekzema D, Meltzer MS, Gendelman HE.

J Virol. 1992 Dec;66(12):7543-8.

48.

Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro.

Barbas CF 3rd, Björling E, Chiodi F, Dunlop N, Cababa D, Jones TM, Zebedee SL, Persson MA, Nara PL, Norrby E, et al.

Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):9339-43.

49.

Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus.

Layne SP, Merges MJ, Dembo M, Spouge JL, Conley SR, Moore JP, Raina JL, Renz H, Gelderblom HR, Nara PL.

Virology. 1992 Aug;189(2):695-714.

PMID:
1386485
50.

Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.

Haigwood NL, Nara PL, Brooks E, Van Nest GA, Ott G, Higgins KW, Dunlop N, Scandella CJ, Eichberg JW, Steimer KS.

J Virol. 1992 Jan;66(1):172-82.

Supplemental Content

Support Center